4082.0 Accessing Care for Co-occurring Drug Use & Infectious Disease

Tuesday, October 30, 2012: 10:30 AM - 12:00 PM
This session examines challenges to accessing care for co-occurring drug use and infectious disease. Racial/ethnic disparities in HIV prevalence among drug users persist in the US, and Hepatitis C remains prevalent among drug users. Additionally, HIV and Hepatitis C testing and accessing medical care is challenging for many drug users, due to barriers including stigma and discrimination. Substance use among HIV-infected adolescents is associated with sexual transmission-risk-behavior and suboptimal antiretroviral-therapy adherence. Further, Hepatitis C is the most prevalent chronic disease among injection drug users, yet relatively few have been treated. Co-morbid psychiatric illness, fragmentation of care, low social support, and concerns about adverse effects are significant barriers to evaluation and treatment.
Session Objectives: Describe how discrimination affects healthcare access and satisfaction. Identify HIV risk behaviors and patterns of drug use in HIV infected persons. Explain benefits of peer support on HCV treatment.

Associations of Perceived Drug Use and Race/Ethnicity Based Discrimination On Healthcare Access and Satisfaction Among People Who Use Drugs
Courtney McKnight, MPH, Carmen L. Masson, PhD, Enrique R. Pouget, PhD, Ashly E. Jordan, BA, Lara Coffin, MPH, Randy Seewald, MD, James L. Sorensen, PhD, Don C. Des Jarlais, PhD and David C. Perlman, MD
Alcohol and drug use differences by behaviorally versus perinatally HIV-infected adolescents in care
Margie R. Skeer, ScD, MPH, MSW, Laura M. Bogart, PhD, Elizabeth F. Closson, MSc, Steven A. Safren, PhD, ABPP and Matthew J. Mimiaga, ScD, MPH
Drug treatment utilization among adults receiving HIV prevention services in Los Angeles County
Jo Brocato, PhD, Dennis Fisher, PhD, Grace L. Reynolds, DPA and Mike Janson, MPH
"It's easier to do stuff that's hard when you've got people to back you:" Hepatitis C Peer Education & Support in an Opioid Treatment Program
Robert Roose, MD, MPH, Irene Soloway, PA, Lauren Cockerham-Colas, MPH, Abigail Batchelder, MPH, MA and Alain Litwin, MD, MPH, MS

See individual abstracts for presenting author's disclosure statement and author's information.

Organized by: Alcohol, Tobacco, and Other Drugs
Endorsed by: HIV/AIDS, Medical Care

CE Credits: Medical (CME), Health Education (CHES), Nursing (CNE), Public Health (CPH) , Masters Certified Health Education Specialist (MCHES)